---
title: Nirsevimab
slug: nirsevimab
qid: 
snapshot: enwiki-001378624083
content_hash: 
license: CC BY-SA 4.0
source: https://en.wikipedia.org/w/index.php?oldid=1378624083
tags: [20503538, 23118434, 23534022, 23603337, 24409354, 25463724, 26220375, 26706142, 32308905, 40590544, 50769796, 61955657, 68150358, 70480166, 71602501]
---

# Nirsevimab

> [!note] Provenance
> Snapshot `enwiki-001378624083` · content root `…`
> Derived from <https://en.wikipedia.org/w/index.php?oldid=1378624083> · Licensed CC BY-SA 4.0

Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus (RSV). It is a respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor that is designed to bind to the fusion protein on the surface of the RSV virus. The most common side effects are rash, fever and injection site reactions (such as redness, swelling and pain where the injection is given). It was developed by AstraZeneca and Sanofi. Nirsevimab was approved for medical use in both the European Union and the United Kingdom in November 2022, in Canada in April 2023, and in the United States in July 2023.

Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus (RSV). It is a respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor that is designed to bind to the fusion protein on the surface of the RSV virus. The most common side effects are rash, fever and injection site reactions (such as redness, swelling and pain where the injection is given). It was developed by AstraZeneca and Sanofi. Nirsevimab was approved for medical use in both the European Union and the United Kingdom in November 2022, in Canada in April 2023, and in the United States in July 2023.
